NewsBenzinga辉瑞宣布,ELREXFIO 在 Phase 3 MagnetisMM-32 试验中的顶线结果显示,对于在抗 CD38 治疗和来那度胺后疾病进展的患者具有临床意义且统计学显著的获益,中位无进展生存期尚未达到 辉瑞宣布,ELREXFIO 在 Phase 3 MagnetisMM-32 试验中的顶线结果显示,对于在抗 CD38 治疗和来那度胺后疾病进展的患者具有临床意义且统计学显著的获益,中位无进展生存期尚未达到 Benzinga 2026.10.27 10:49 (GMT+0) Open on Benzinga Other news Ark Invest Makes Big Crypto-Related Buys Yesterday While Selling $84.8M in Nvidia Stock Abraxas Capital Closes Most of Its Hyperliquid Shorts, Account Value Down to Just $22.4 Million Nvidia Falls 35% From Record High, Short Sellers Sit on $24 Billion in Paper Profits Nvidia Director Reportedly Warns of ‘Irreplaceable Talent’ Loss: Board Urged to Bring Back Jensen Huang as NVDA Stock Slips Elon Musk’s Cybercab Ambitions Get a $3.3 Billion Boost — Tesla Plans 1 Million Units a Year at Berlin Factory Evernorth Has Written Down Its Pre-Listing XRP Holdings by 60%
Nvidia Director Reportedly Warns of ‘Irreplaceable Talent’ Loss: Board Urged to Bring Back Jensen Huang as NVDA Stock Slips
Elon Musk’s Cybercab Ambitions Get a $3.3 Billion Boost — Tesla Plans 1 Million Units a Year at Berlin Factory